Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Recurrence 2Lymphoma, Non-Hodgkin 2Leukemia, Lymphocytic, Chronic, B-Cell 2Pyloric Stenosis, Hypertrophic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia 1Burkitt Lymphoma 1

Interventions

Rituximab 67Cyclophosphamide 52fludarabine phosphate 44Whole-Body Irradiation 36Mycophenolic Acid 33Peripheral Blood Stem Cell Transplantation 29Tacrolimus 27Busulfan 24Cyclosporine 21Antilymphocyte Serum 21Melphalan 18Filgrastim 16Etoposide 15Methotrexate 14Radiotherapy 12Lenalidomide 12Cord Blood Stem Cell Transplantation 12fludarabine 10Sirolimus 10Granulocyte Colony-Stimulating Factor 10Dexamethasone 9Bendamustine Hydrochloride 9Prednisone 8Bortezomib 8thymoglobulin 7idelalisib 7Flow Cytometry 7Calcium Dobesilate 7ibritumomab tiuxetan 6Methylprednisolone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, B-Cell, Marginal Zone × tafasitamab × Clear all
NCT04680052 2025-12-22

InMIND

Incyte Corporation

Phase 3 Active not recruiting
654 enrolled 40 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡